Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

1 booster (and Moderna’s, though the TGA has not approved ... So who should get vaccinated, and when? Updating vaccines to deal with mutating viruses is not a new concept. It has been happening for ...

If you missed the early fall push for flu and COVID-19 vaccines, it’s not too late. Health officials say it’s important to get vaccinated ahead of the holidays, when respiratory bugs tend to spread ...

For young, healthy people who may be wondering, “do I need a COVID booster at all?”, having one annually is sensible.

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

RNA vaccines saved lives during the COVID-19 pandemic, but older people had less of an immune response to the vaccines than ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...

By the fourth shot, she winced. But six vaccines later, she was still free of tears — and she’s up-to-date on her school ...